论文部分内容阅读
目的探讨立体定向放射治疗联合盐酸吉西他滨治疗局部晚期胰腺癌患者的疗效及预后。方法选取2012年5月至2016年5月间长沙市中心医院收治的无法手术切除的76例局部晚期胰腺癌患者,按照治疗方式不同将患者分为观察组与对照组,每组38例。观察组患者采用立体定向放射治疗联合盐酸吉西他滨治疗,对照组患者采用盐酸吉西他滨治疗。观察两组患者近期治疗疗效、远期治疗疗效及不良反应情况。结果观察组患者总有效率为78.9%,明显高于对照组患者的36.8%,差异有统计学意义(P<0.05)。观察组患者第1年和第2年复发率分别为10.5%和26.3%,均明显低于对照组患者的31.6%和47.4%,第1年和第2年生存率分别为76.3%和50.0%,均明显高于对照组的55.3%和26.3%,两组比较,差异均有统计学意义(均P<0.05)。两组患者治疗期间主要不良反应比较,差异均无统计学意义(均P>0.05)。结论立体定向放射治疗联合盐酸吉西他滨对局部晚期胰腺癌患者相对安全有效,能较好控制患者病情,提高患者生存时间。
Objective To investigate the efficacy and prognosis of stereotactic radiotherapy combined with gemcitabine hydrochloride in patients with locally advanced pancreatic cancer. Methods From July 2012 to May 2016, 76 patients with locally advanced pancreatic cancer who were not surgically resected in Changsha Central Hospital were divided into observation group and control group according to different treatment methods, with 38 cases in each group. Patients in the observation group were treated with stereotactic radiotherapy combined with gemcitabine hydrochloride, and patients in the control group were treated with gemcitabine hydrochloride. Observation of two groups of patients with short-term efficacy, long-term efficacy and adverse reactions. Results The total effective rate of the observation group was 78.9%, which was significantly higher than that of the control group (36.8%), the difference was statistically significant (P <0.05). The recurrence rates in the first year and the second year in the observation group were 10.5% and 26.3%, respectively, which were significantly lower than those in the control group (31.6% and 47.4%, respectively). The first and second year survival rates were 76.3% and 50.0% , Which were significantly higher than those in the control group (55.3% and 26.3% respectively). There were significant differences between the two groups (all P <0.05). There was no significant difference in major adverse reactions between the two groups during treatment (all P> 0.05). Conclusion Stereotactic radiotherapy combined with gemcitabine hydrochloride is relatively safe and effective for patients with locally advanced pancreatic cancer, and can better control the patient’s condition and improve the survival time of patients.